Legal & General Group Plc increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 13.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 81,297 shares of the biotechnology company’s stock after purchasing an additional 9,664 shares during the period. Legal & General Group Plc owned approximately 0.18% of United Therapeutics Corporation worth $10,547,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Focused Wealth Management Inc increased its position in shares of United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 140 shares during the period. Advisory Services Network LLC bought a new position in shares of United Therapeutics Corporation in the first quarter worth $147,000. Daiwa Securities Group Inc. increased its position in shares of United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 200 shares during the period. Campbell & CO Investment Adviser LLC bought a new position in shares of United Therapeutics Corporation in the first quarter worth $204,000. Finally, Eagle Global Advisors LLC bought a new position in shares of United Therapeutics Corporation in the second quarter worth $206,000.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,247 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $126.40, for a total value of $157,620.80. Following the transaction, the chief executive officer now directly owns 2,316 shares in the company, valued at approximately $292,742.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Raymond Dwek sold 3,490 shares of the company’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $131.71, for a total value of $459,667.90. The disclosure for this sale can be found here. Insiders sold a total of 24,606 shares of company stock worth $3,207,882 over the last 90 days. Corporate insiders own 7.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Position Lifted by Legal & General Group Plc” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/04/united-therapeutics-corporation-uthr-position-lifted-by-legal-general-group-plc.html.

United Therapeutics Corporation (UTHR) opened at 133.35 on Monday. The firm has a 50-day moving average price of $130.11 and a 200-day moving average price of $131.91. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a market cap of $5.79 billion, a PE ratio of 15.46 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The business had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. United Therapeutics Corporation’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.42 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current year.

A number of brokerages recently commented on UTHR. UBS AG restated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC restated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $134.50.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.